Medimmune Limited

Abbott Laboratories Corporation

Ethan Grant

Meina Liang

Koustubh Ranade

Partha S Chowdhury

Reena Varkey

Yen-Wah Lee

Katie Streicher

Yihong Yao

Lydia Greenlees

Melissa Parker

Susan E Brophy

Bruce J Dille

Carlos Chavez

Tomas M Mustelin

Gerard Davis

Nicolette Jeanblanc

Rachel Patricia Moate

Alex Godwood

Zhengbin Yao

Martin Michael Kari Schwickart

The present disclosure relates to the use of anti-PAD4 autoantibodies as a clinical biomarker for rheumatoid arthritis (RA) treatment. The disclosure further provides an assay to detect anti-PAD4 autoantibodies, assay kits for the detection of anti-PAD4 autoantibodies, as well as computer implemented diagnostic methods.

Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis

This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.

Methods of using antibodies to determine periostin levels in a sample

Monoclonal antibodies which bind human periostin

Growing community of inventors

Gaithersburg, MD, United States of America

Ethan Grant